Subscribe to this topic via RSS or ATOM
Topic - Stephanie Yao
No Stories Found
"We are reviewing the letter and are working to respond as quickly as possible," she said. "The FDA has received a great deal of public input from various stakeholders during the comment period on the proposed rule."